MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Ylösmäki, Erkko ^a   Lavilla Alonso, Sergio ^a   Jäämaa, Sari ^a,b   Vähä Koskela, Markus ^b   af Hällström, Taija ^b   Hemminki, Akseli ^b   Arola, Johanna ^a   Mäkisalo, Heikki ^c   Saksela, Kalle ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; LIVER ENZYME; MICRORNA; MICRORNA 122; ONCOLYTIC ADENOVIRUS;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; E1A GENE; ENZYME BLOOD LEVEL; EX VIVO STUDY; GENE INSERTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER INJURY; LIVER METASTASIS; LIVER TOXICITY; LUNG CANCER; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; RISK REDUCTION; TUMOR XENOGRAFT; VIRUS GENE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENOME, VIRAL; HUMANS; LIVER; LUNG NEOPLASMS; MICE; MICRORNAS; NEOPLASM METASTASIS; ONCOLYTIC VIRUSES; ORGAN SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

ADENOVIRIDAE; MUS;

EID: 84872787899     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054506     Document Type: Article

References (54)

1. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
2. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ, (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-158.
3. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
4. Ebert MS, Sharp PA, (2012) Roles for microRNAs in conferring robustness to biological processes. Cell 149: 515-524.
5. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
6. Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW, (2007) miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 26: 293-300.
7. Yu SL, Chen HY, Yang PC, Chen JJ, (2007) Unique MicroRNA signature and clinical outcome of cancers. DNA Cell Biol 26: 283-292.
8. Grassmann R, Jeang KT, (2008) The roles of microRNAs in mammalian virus infection. Biochimica et biophysica acta 1779: 706-711.
9. Russo A, Potenza N, (2011) Antiviral effects of human microRNAs and conservation of their target sites. FEBS letters 585: 2551-2555.
10. Cullen BR, (2011) Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev 25: 1881-1894.
11. Kelly EJ, Russell SJ, (2009) MicroRNAs and the regulation of vector tropism. Mol Ther 17: 409-416.
12. Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R, (2008) Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4: 239-248.
13. Kelly EJ, Hadac EM, Greiner S, Russell SJ, (2008) Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14: 1278-1283.
14. Pesonen S, Kangasniemi L, Hemminki A, (2011) Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 8: 12-28.
15. Russell SJ, Peng KW, Bell JC, (2012) Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
16. Yamamoto M, Curiel DT, (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther 18: 243-250.
17. Campos SK, Barry MA, (2007) Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 7: 189-204.
18. Dorer DE, Nettelbeck DM, (2009) Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61: 554-571.
19. Heise C, Kirn DH, (2000) Replication-selective adenoviruses as oncolytic agents. J Clin Invest 105: 847-851.
20. Sullivan DE, Dash S, Du H, Hiramatsu N, Aydin F, et al. (1997) Liver-directed gene transfer in non-human primates. Hum Gene Ther 8: 1195-1206.
21. Duncan SJ, Gordon FC, Gregory DW, McPhie JL, Postlethwaite R, et al. (1978) Infection of mouse liver by human adenovirus type 5. J Gen Virol 40: 45-61.
22. Ylösmäki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, et al. (2008) Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 82: 11009-11015.
23. Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, et al. (2009) Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog 5: e1000440.
24. Cawood R, Wong SL, Di Y, Baban DF, Seymour LW, (2011) MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity. PLoS One 6: e16152.
25. Leja J, Nilsson B, Yu D, Gustafson E, Akerstrom G, et al. (2010) Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS One 5: e8916.
26. Alemany R, Curiel DT, (2001) CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8: 1347-1353.
27. Chang J, Nicolas E, Marks D, Sander C, Lerro A, et al. (2004) miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1: 106-113.
28. De Kanter R, Olinga P, De Jager MH, Merema MT, Meijer DK, et al. (1999) Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney. Toxicol In Vitro 13: 737-744.
29. Olinga P, Groen K, Hof IH, De Kanter R, Koster HJ, et al. (1997) Comparison of five incubation systems for rat liver slices using functional and viability parameters. J Pharmacol Toxicol Methods 38: 59-69.
30. Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K, et al. (2006) Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. Journal of virology 80: 3549-3558.
31. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, et al. (2001) E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 12: 219-226.
32. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A 3rd, et al (2003) Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 21: 1498-1504.
33. Berk AJ, (2005) Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24: 7673-7685.
34. Harbour JW, Dean DC, (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14: 2393-2409.
35. Hitt MM, Graham FL, (1990) Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 179: 667-678.
36. Ikeda T, Sawada N, Fujinaga K, Minase T, Mori M, (1989) H-ras gene is expressed at the G1 phase in primary cultures of hepatocytes. Exp Cell Res 185: 292-296.
37. Loyer P, Cariou S, Glaise D, Bilodeau M, Baffet G, et al. (1996) Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1. J Biol Chem 271: 11484-11492.
38. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, et al. (2002) Identification of tissue-specific microRNAs from mouse. Curr Biol 12: 735-739.
39. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414.
40. Liang Y, Ridzon D, Wong L, Chen C, (2007) Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 8: 166.
41. Thomson JM, Parker J, Perou CM, Hammond SM, (2004) A custom microarray platform for analysis of microRNA gene expression. Nat Methods 1: 47-53.
42. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
43. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114: 965-971.
44. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
45. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, et al. (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284: 32015-32027.
46. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, et al. (2009) MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571-1582.
47. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS, (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
48. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, et al. (2006) Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99: 671-678.
49. Cody JJ, Douglas JT, (2009) Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 16: 473-488.
50. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J, (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858-3863.
51. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, et al. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
52. Hamilton MA, Russo RC, Thurston RV (1977) Trimmed Spearman-Kärber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol 11.
53. Euhus DM, Hudd C, LaRegina MC, Johnson FE, (1986) Tumor measurement in the nude mouse. J Surg Oncol 31: 229-234.
54. Tomayko MM, Reynolds CP, (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154.